tadalafil

ApprovedWithdrawn

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Gastroparesis

Conditions

Gastroparesis, Diabetic Gastroparesis, Nausea, Vomiting

Trial Timeline

Apr 1, 2011 → Dec 1, 2013

NCT ID

NCT01326117

About tadalafil

tadalafil is a approved stage product being developed by Eli Lilly for Gastroparesis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01326117. Target conditions include Gastroparesis, Diabetic Gastroparesis, Nausea.

What happened to similar drugs?

5 of 7 similar drugs in Gastroparesis were approved

Approved (5) Terminated (3) Active (2)

✅Mosapride + domperidoneSumitomo PharmaApproved

✅Cisapride + PlaceboJohnson & JohnsonApproved

✅TegaserodNovartisApproved

✅Immediate-release omeprazole + Delayed-release omeprazoleBausch HealthApproved

🔄TradipitantVanda PharmaceuticalsPhase 3

🔄Tradipitant + Placebo + Open Label TradipitantVanda PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02252367	Approved	Completed	Dec 1, 2015	Jun 1, 2020	Prostatic Hyperplasia
NCT02224846	Approved	Completed	Oct 1, 2014	May 1, 2017	Erectile Dysfunction
NCT01326117	Approved	Withdrawn	Apr 1, 2011	Dec 1, 2013	Gastroparesis
NCT01324999	Phase 2/3	Completed	Mar 1, 2011	Oct 1, 2013	Pulmonary Hypertension
NCT01183650	Phase 1	Completed	Jul 1, 2010	Apr 1, 2011	Benign Prostatic Hyperplasia
NCT01066845	Pre-clinical	Completed	Jan 1, 2010	Aug 1, 2014	Pulmonary Arterial Hypertension
NCT00822354	Pre-clinical	Completed	Sep 1, 2008	Apr 1, 2010	Raynaud
NCT00157326	Phase 2	Completed	Sep 1, 2005	Jun 1, 2006	Hypertension
NCT00333281	Approved	Completed	Jun 1, 2005	Aug 1, 2006	Erectile Dysfunction
NCT00422578	Approved	Completed	Oct 1, 2004	Sep 1, 2005	Impotence
NCT00421083	Phase 3	Completed	Sep 1, 2004	Jun 1, 2005	Erectile Dysfunction
NCT00547417	Phase 3	Completed	Jul 1, 2003	Mar 1, 2004	Impotence
NCT00547599	Approved	Completed	Apr 1, 2003	Jan 1, 2004	Impotence

Competing Products

19 competing products in Gastroparesis

See all competitors

Product	Company	Stage	Hype Score
tadalafil + tadalafil + placebo	Eli Lilly	Phase 2	35
Granisetron	Kyowa Kirin	Phase 2	27
Mosapride + domperidone	Sumitomo Pharma	Approved	39
Cisapride + Placebo	Johnson & Johnson	Approved	35
Cisapride + Placebo	Johnson & Johnson	Approved	35
Naloxegol 25 MG Oral Tablet [Movantik] + Placebo Oral Tablet	AstraZeneca	Phase 2	27
Sitagliptin + Placebo	Merck	Phase 1	29
Tegaserod	Novartis	Approved	35
Reglan ODT	UCB	Pre-clinical	26
Hemin + Albumin	Recordati	Phase 2	32
CNSA-001 + Placebo	PTC Therapeutics	Phase 2	32
Immediate-release omeprazole + Delayed-release omeprazole	Bausch Health	Approved	37
Velusetrag + Placebo	Theravance Biopharma	Phase 2	29
velusetrag dose 1 + velusetrag dose 2 + velusetrag dose 3 + placebo	Theravance Biopharma	Phase 2	29
IW-9179 + Matching Placebo	Ironwood Pharmaceuticals	Phase 2	29
VLY-686 (Tradipitant)	Vanda Pharmaceuticals	Phase 2	25
Tradipitant	Vanda Pharmaceuticals	Phase 3	37
Tradipitant	Vanda Pharmaceuticals	Pre-clinical	20
Tradipitant + Placebo + Open Label Tradipitant	Vanda Pharmaceuticals	Phase 3	30